Department of Psychology, University of Balearic Islands (UIB), 07122 Palma, Spain.
Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma, Spain.
Int J Environ Res Public Health. 2021 Oct 24;18(21):11156. doi: 10.3390/ijerph182111156.
Studies about the survival of patients with prostate cancer by stage or risk of progression are scarce. The aims of this study were (1) to determine the cause-specific survival by risk in prostate cancer patients in Mallorca diagnosed in the period 2006-2011; (2) to identify the factors that explain and predict the likelihood of survival and the risk of dying from this type of cancer; and (3) to determine the distribution of prostate cancer by risk in the patients in Mallorca diagnosed in the period 2006-2011. Incident prostate cancer cases diagnosed between 2006 and 2011 were identified through the Mallorca Cancer Registry. We collected age; date and method of diagnosis; date of follow-up or death; T, N, M and stage according to the TNM 7th edition; Gleason score; prostate-specific antigen (PSA); histology according to the International Classification of Diseases for Oncology (ICD-O) 3rd edition, comorbidities and treatments. We calculated risk in four categories: low, medium, high and very high. The end point of follow-up was 31 December 2014. Multiple imputation (MI) was performed to estimate cases with unknown risk. We identified 2921 cases. Five years after diagnosis, survival after MI was 89% globally, and was 100% for low-risk cases, 96% for medium risk, 93% for high risk and 69% for very-high-risk cases. Cases with histology other than adenocarcinoma, with high (and especially very high) risk, as well as with systemic, mixed and observation/unspecified treatments had worse prognoses.
关于按阶段或进展风险对前列腺癌患者生存情况的研究较少。本研究的目的是：(1) 确定 2006-2011 年期间在马略卡岛诊断的前列腺癌患者的风险特异性生存率；(2) 确定解释和预测生存概率及死于该类型癌症风险的因素；(3) 确定 2006-2011 年期间在马略卡岛诊断的前列腺癌患者的风险分布。通过马略卡癌症登记处确定了 2006 年至 2011 年间诊断出的偶发性前列腺癌病例。我们收集了年龄；诊断日期和方法；随访或死亡日期；T、N、M 和根据第 7 版 TNM 分期的分期；Gleason 评分；前列腺特异性抗原 (PSA)；根据国际肿瘤学疾病分类 (ICD-O) 第 3 版的组织学；合并症和治疗。我们将风险分为四个类别：低、中、高和非常高。随访的终点是 2014 年 12 月 31 日。对未知风险的病例进行了多次插补 (MI)。我们确定了 2921 例病例。在诊断后 5 年，经 MI 估计的生存率为全球 89%，低风险病例为 100%，中风险为 96%，高风险为 93%，极高风险为 69%。组织学不是腺癌、高风险（尤其是极高风险）以及全身性、混合性和观察/未指定治疗的病例预后较差。
